Genelux’s (NASDAQ:GNLX – Get Free Report) lock-up period is set to end on Tuesday, July 25th. Genelux had issued 2,500,000 shares in its IPO on January 26th. The total size of the offering was $15,000,000 based on an initial share price of $6.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
Genelux Stock Performance
NASDAQ GNLX opened at $29.54 on Tuesday. The stock’s fifty day moving average price is $29.68. Genelux has a 52 week low of $5.35 and a 52 week high of $40.98.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Dubuque Bank & Trust Co. acquired a new position in shares of Genelux during the second quarter worth $305,000. LifeSteps Financial Inc. acquired a new position in shares of Genelux during the second quarter worth $438,000. AE Wealth Management LLC acquired a new position in shares of Genelux during the second quarter worth $434,000. State Street Corp acquired a new position in shares of Genelux during the first quarter worth $214,000. Finally, Geode Capital Management LLC acquired a new position in shares of Genelux during the first quarter worth $1,046,000. 1.17% of the stock is owned by institutional investors and hedge funds.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.
Further Reading
- Five stocks we like better than Genelux
- Is It Time To Take Another Bite Of Chewy, Inc?
- GreenPower Motor Company Shifts Into High Gear
- Is the Microsoft Deal Driving Applied Optoelectronics 300% Gain?
- Can Unity Software Sustain The Momentum?
- Nvidia Invested $50 million into This AI Drug Discovery Biotech
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
